Armistice Capital, LLC Aeterna Zentaris Inc. Transaction History

Armistice Capital, LLC

  • $6.02 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020
SELL
$0.77 - $1.08 $369,600 - $518,400
-480,000 Closed
0 $0
Q3 2019

Nov 14, 2019
BUY
$1.0 - $2.97 $480,000 - $1.43 Million
480,000 New
480,000 $494,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email